SCHEMBL573187

SCHEMBL573187

O=C(O)c1ccc2sccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 4/20 0.63
WNT3A P56704 4/20 0.63
MRGPRX4 Q96LA9 2/20 0.55
CSNK2A1 P68400 1/20 0.51
NAMPT P43490 1/20 0.49
CYP2A6 P11509 2/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CHRNA7 P36544 1/20 0.46
HTR3A P46098 1/20 0.46
TSHR P16473 1/20 0.45
KDM4E B2RXH2 2/20 0.44
HKDC1 Q2TB90 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GPR35 Q9HC97 1/20 0.44
PTPRC P08575 1/20 0.44
PTPN6 P29350 1/20 0.44
PTPN11 Q06124 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30489890 1.00 CTNNB1 (0.63) CTNNB1WNT3AMRGPRX4CSNK2A1NAMPT
SCHEMBL16595380 0.85 CTNNB1 (0.59) CTNNB1WNT3AMRGPRX4CSNK2A1NAMPT
SCHEMBL30445266 0.84 MRGPRX4 (0.55) CTNNB1WNT3AMRGPRX4CSNK2A1NPC1
SCHEMBL1891764 0.84 MRGPRX4 (0.55) CTNNB1WNT3AMRGPRX4CSNK2A1NPC1
SCHEMBL30446776 0.82 CTNNB1 (0.57) CTNNB1WNT3ANAMPTCYP2A6NPC1
SCHEMBL826934 0.82 CTNNB1 (0.57) CTNNB1WNT3ANAMPTCYP2A6NPC1
SCHEMBL1021640 0.82 CTNNB1 (0.57) CTNNB1WNT3AMRGPRX4CSNK2A1NAMPT
SCHEMBL29503181 0.82 CTNNB1 (0.57) CTNNB1WNT3ACSNK2A1NAMPTCYP2A6
Hydrochloric Acid SCHEMBL31483491 0.82 MRGPRX4 (0.54) CTNNB1WNT3AMRGPRX4CSNK2A1NPC1
SCHEMBL3352794 0.82 CTNNB1 (0.57) CTNNB1WNT3ACSNK2A1NAMPTCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863766-B1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT INC (US) 2015-05-20 EP claimed
CN-103923765-A Detergent Composition For Process Of Manufacturing Semiconductors And Displays COWON INNOTECH INC 2014-07-16 CN claimed
EP-2227468-A1 AMINOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP claimed
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 EP claimed
WO-2009068467-A1 AMINOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO claimed
EP-1863766-A2 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI Pharmaceuticals, Inc. (US) 2007-12-12 EP claimed
US-20070072892-A1 Amino-aza-adamantane derivatives and methods of use ABBOTT LABORATORIES 2007-03-29 US claimed
US-20060229337-A1 Certain substituted amides, method of making, and method of use thereof GILEAD CONNECTICUT, INC. 2006-10-12 US claimed
WO-2006099075-A2 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2006-09-21 WO claimed
WO-2026103694-A1 HDAC INHIBITOR, AND PREPARATION AND USE THEREOF 赛岚(杭州)生物医药科技有限公司 2026-05-21 WO disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS NATIONAL HEALTH RES INST (TW) 2026-02-19 US disclosed
EP-1044973-A2 Process for the dehalogenation of thiochroman and dihydrobenzothiophene derivatives American Cyanamid Company (US) 2000-10-18 EP disclosed
EP-1042313-A1 BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY Allergan Sales, Inc. (US) 2000-10-11 EP disclosed
EP-1031572-A1 PYRIDYLPYRROLE DERIVATIVES Sankyo Company Limited (JP) 2000-08-30 EP disclosed
WO-1999033821-A1 BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY ALLERGAN SALES, INC. (US) 1999-07-08 WO disclosed
US-4609739-A Synthetic routes to benzofurans and benzothiophenes and intermediates therefor THE UPJOHN COMPANY (US) 1986-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS OPRK1, OPRD1, OPRM1 CTNNB1 3269/4885WNT3A 4668/4885MRGPRX4 136/4885
US-20070072892-A1 Amino-aza-adamantane derivatives and methods of use CHRNA7, CHRNA5, CHRNA1 CTNNB1 3650/4885WNT3A 1953/4885MRGPRX4 738/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CTNNB1 2402/4885WNT3A 1584/4885MRGPRX4 453/4885
US-20060229337-A1 Certain substituted amides, method of making, and method of use thereof BTK, SYK, MYD88 CTNNB1 4757/4885WNT3A 4824/4885MRGPRX4 627/4885
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 CTNNB1 3514/4885WNT3A 3939/4885MRGPRX4 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.